文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

急性冠状动脉综合征患者伴或不伴可标准修正的心血管风险因素的住院死亡率和治疗:CCC-ACS 项目的结果。

In-Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC-ACS Project.

机构信息

Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China.

National Clinical Research Center for Cardiovascular Diseases Beijing China.

出版信息

J Am Heart Assoc. 2024 Oct;13(19):e029252. doi: 10.1161/JAHA.122.029252. Epub 2024 Sep 18.


DOI:10.1161/JAHA.122.029252
PMID:39291502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11681477/
Abstract

BACKGROUND: Patients with acute coronary syndrome without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, smoking, dyslipidemia, diabetes) have not been well studied, with little known about their characteristics, quality of care, or outcomes. We sought to systematically analyze patients with ACS without SMuRFs, especially to evaluate the effectiveness of guideline-directed medical therapy for these patients. METHODS AND RESULTS: In the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) project (2014-2019), we examined the presence and absence of SMuRFs and features among 89 462 patients with initial acute coronary syndrome. The main outcome was in-hospital all-cause mortality. Among eligible patients, 11.0% had none of the SMuRFs (SMuRF-less). SMuRF-less patients had higher in-hospital mortality (unadjusted hazard ratio [HR], 1.49 [95% CI, 1.19-1.87]). After adjustment for clinical characteristics and treatments, the associations between SMuRF status and in-hospital mortality persisted (adjusted HR, 1.35 [95% CI, 1.07-1.70]). Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins) was not associated with lower mortality (adjusted HR, 0.98 [95% CI, 0.58-1.67]) in SMuRF-less patients, unlike the association in patients with SMuRFs (adjusted HR, 0.80 [95% CI, 0.66-0.98]). Sensitivity analyses were consistent with these results. CONCLUSIONS: SMuRF-less patients were associated with an increased risk of in-hospital mortality. Guideline-directed medical therapy was less effective in SMuRF-less patients than in patients with SMuRFs. Dedicated studies are needed to confirm the optimal therapy for SMuRF-less patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02306616.

摘要

背景:患有不伴有标准可修正心血管风险因素(SMuRFs;高血压、吸烟、血脂异常、糖尿病)的急性冠脉综合征患者的研究还不够充分,对于这些患者的特征、医疗护理质量和结局了解甚少。我们试图系统地分析不伴有 SMuRFs 的 ACS 患者,尤其是评估这些患者的指南指导的药物治疗的效果。

方法和结果:在 CCC-ACS(改善中国心血管疾病管理-急性冠脉综合征)项目(2014-2019 年)中,我们检查了 89462 例初始急性冠脉综合征患者中 SMuRFs 的存在情况和特征。主要结局是院内全因死亡率。在符合条件的患者中,11.0%的患者不伴有任何 SMuRFs(SMuRF-无)。SMuRF-无患者的院内死亡率更高(未经调整的危险比[HR],1.49[95%置信区间,1.19-1.87])。在调整了临床特征和治疗后,SMuRF 状态与院内死亡率之间的关联仍然存在(调整后的 HR,1.35[95%置信区间,1.07-1.70])。指南指导的最佳药物治疗(接受血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂和他汀类药物)与 SMuRF-无患者的死亡率降低无关(调整后的 HR,0.98[95%置信区间,0.58-1.67]),而与伴有 SMuRFs 的患者的死亡率降低相关(调整后的 HR,0.80[95%置信区间,0.66-0.98])。敏感性分析结果与这些结果一致。

结论:SMuRF-无患者与院内死亡率增加相关。指南指导的药物治疗在 SMuRF-无患者中的效果不如伴有 SMuRFs 的患者。需要专门的研究来确定 SMuRF-无患者的最佳治疗方法。

注册:网址:https://www.clinicaltrials.gov;唯一标识符:NCT02306616。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7300/11681477/b175e4e12dc8/JAH3-13-e029252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7300/11681477/b175e4e12dc8/JAH3-13-e029252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7300/11681477/b175e4e12dc8/JAH3-13-e029252-g001.jpg

相似文献

[1]
In-Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC-ACS Project.

J Am Heart Assoc. 2024-10

[2]
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.

Lancet. 2021-3-20

[3]
In-Hospital Outcomes in Patients With Acute Myocardial Infarction and No Standard Modifiable Cardiovascular Risk Factors Across Varying Body Mass Index: Findings From the CCC-ACS Project.

J Am Heart Assoc. 2025-4

[4]
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients.

Int J Cardiol. 2023-1-15

[5]
Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Less) Study.

Vasc Health Risk Manag. 2025-2-5

[6]
Sex Differences in In-Hospital Management and Outcomes of Patients With Acute Coronary Syndrome.

Circulation. 2019-4-9

[7]
Characteristics, Treatment, and In-Hospital Outcomes of Older Patients With STEMI Without Standard Modifiable Risk Factors.

JACC Asia. 2023-11-21

[8]
Prevalence and outcomes of patients with SMuRF-less acute coronary syndrome undergoing percutaneous coronary intervention.

Open Heart. 2024-6-5

[9]
In-hospital and 1-year outcomes of patients without modifiable risk factors presenting with acute coronary syndrome undergoing PCI: a Sex-stratified analysis.

Front Cardiovasc Med. 2023-12-20

[10]
Standard modifiable cardiovascular risk factors in patients with acute coronary syndrome: A report from multicenter percutaneous coronary intervention registry.

J Cardiol. 2023-6

引用本文的文献

[1]
Lipoprotein(a) and its linear association with all-cause and cardiovascular mortality in patients with acute coronary syndrome.

Front Endocrinol (Lausanne). 2025-5-27

[2]
Direct economic burden of acute coronary syndromes in the Portuguese National Health Service-facts and trends between 2002 and 2022.

Front Public Health. 2025-3-18

[3]
In-Hospital Outcomes in Patients With Acute Myocardial Infarction and No Standard Modifiable Cardiovascular Risk Factors Across Varying Body Mass Index: Findings From the CCC-ACS Project.

J Am Heart Assoc. 2025-4

[4]
Long-term outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention without standard modifiable cardiovascular risk factors: findings from the OPT-CAD cohort.

BMC Med. 2025-2-24

本文引用的文献

[1]
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients.

Int J Cardiol. 2023-1-15

[2]
Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry.

BMC Med. 2022-7-6

[3]
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study.

Eur Heart J. 2022-5-7

[4]
Diagnosis and Treatment of Acute Coronary Syndromes: A Review.

JAMA. 2022-2-15

[5]
The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease.

Eur Heart J. 2022-2-22

[6]
Sleep Apnea-Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality.

Am J Respir Crit Care Med. 2022-1-1

[7]
Coronary artery disease in the absence of traditional risk factors: a call for action.

Eur Heart J. 2021-10-1

[8]
Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells.

Nat Biotechnol. 2021-10

[9]
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.

Lancet. 2021-3-20

[10]
A risk score to predict in-hospital mortality in patients with acute coronary syndrome at early medical contact: results from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) Project.

Ann Transl Med. 2021-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索